drugset / Trial / NCT04612894
Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer
NaSingle-groupOpen-labelTreatment
Summary
To determine the efficacy and safety of anti-PD-1 antibody Camrelizumab combined with Apatinib for neoadjuvant therapy in locally advanced thyroid cancer.
Timeline
- Start
- 2020-12-01
- Primary completion
- 2022-12-01
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Rivoceranib | Small molecule | 250 mg | Oral |